Mitsubishi Tanabe Pharma’s History since Its Establishment

2007

- **October**: Establishment of Mitsubishi Tanabe Pharma through the merger of Tanabe Seiyaku and Mitsubishi Pharma (President and Representative Director, Natsuki Hayama)

2008

- **April**: Establishment of Tanabe Seiyaku Hanbai, a subsidiary handling generic drugs
- **May**: Announcement of Corporate Behavior Charter and Medium-Term Management Plan 08–10: Dynamic Synergy for 2015
- **August**: Choseido Pharmaceutical became a subsidiary, start of comprehensive, equity-based alliance, centered on the generic drugs business
- **October**: Merger of MP-Technopharma and Tanabe Seiyaku Yamaguchi, establishment of Mitsubishi Tanabe Pharma Factory

2009

- **June**: Michihiro Tsuchiya became president and representative director
- **October**: Head Office relocated to Kitahama, Chuo-ku, Osaka
- **November**: Acquisition of domestic sales rights from Kureha for Kremezin, a treatment for chronic kidney disease

2010

- **September**: Acquisition by Novartis, of Switzerland, of approval in the U.S. for Gilenya, a treatment agent for multiple sclerosis

2011

- **March**: Acquisition by Novartis, of Switzerland, of approval in Europe for Gilenya, a treatment agent for multiple sclerosis
- **April**: Transfer of domestic sales of Kremezin, a treatment for chronic kidney disease, from Daiichi Sankyo to the Company
August  ▶ Launch of Lexapro, an anti-depressant, and start of joint sales with Mochida Pharmaceutical

September  ▶ Launch of Simponi, a treatment agent for RA, and start of joint sales with Janssen Pharmaceutical K.K.

October  ▶ Announcement of Medium-Term Management Plan 11−15: New Value Creation

November  ▶ Launch of Imusera, a treatment agent for MS
           ▶ Launch of Telavic, a treatment agent for chronic hepatitis C

2012

March  ▶ Conclusion of strategic joint sales agreement with Daichi Sankyo for Tenelia and Canaglu, treatments for type 2 diabetes mellitus
       ▶ Receipt of Fiscal 2012 Pharmaceutical Society of Japan Award for Drug Research and Development for fingolimod hydrochloride (Imusera), a treatment agent for MS

May  ▶ Relocation of Tokyo Head Office to Koamicho, Nihonbashi, Chuo-ku, Tokyo

July  ▶ Transfer of fine chemical operations to API Corporation and TAISHO TECHNO

September  ▶ Launch of Tenelia, a treatment agent for type 2 diabetes mellitus

October  ▶ Establishment of Japan Blood Products Organization in joint initiative with the Japanese Red Cross Society and transfer of plasma fractionation operations
           ▶ Comprehensive consignment to Collabo-Create of distribution operations that had been handled by MP Logistics
           ▶ Dissolution of comprehensive, equity-based alliance, centered on the generic drug business, with Choseido Pharmaceutical
           ▶ Launch of Tetrabik, a pertussis-diphtheria-tetanus-inactivated polio combined vaccine

2013

March  ▶ Acquisition by Janssen Pharmaceuticals, of the U.S., of approval for Invokana, a treatment agent for adult type 2 diabetes mellitus

June  ▶ Transfer of Tanabe Europe to API Corporation

September  ▶ Medicago, of Canada, a biopharmaceutical company, became a consolidated subsidiary

2014

March  ▶ Receipt of Fiscal 2014 Pharmaceutical Society of Japan Award for Drug Research and Development for SGLT2 inhibitor canagliflozin (Canaglu), a new treatment agent for type 2 diabetes mellitus

April  ▶ Transfer of Mitsubishi Tanabe Pharma Factory's Ashikaga Plant to CMIC HOLDINGS

June  ▶ Masayuki Mitsuka became president and representative director

September  ▶ Launch of Canaglu, a treatment agent for type 2 diabetes mellitus

2015

March  ▶ Termination of plasma fractionation product sales agreement with Japan Blood Products Organization

April  ▶ Relocation of Head Office to Dosho-machi, Chuo-ku, Osaka
       ▶ Transfer of Mitsubishi Tanabe Pharma Factory's Kashima Plant to Sawai Pharmaceutical

May  ▶ Opening of Mitsubishi Tanabe Pharma Historical Museum
       ▶ Receipt of commendation at the Fiscal 2015 National Commendation for Invention for discovery of diabetes treatment agent teneligliptin (Tenelia)

November  ▶ Announcement of Medium-Term Management Plan 16−20: Open Up the Future

2016

January  ▶ Establishment of MT Pharma Singapore in Singapore

February  ▶ Establishment of Mitsubishi Tanabe Pharma America, a pharmaceutical sales company, in the U.S.

May  ▶ Receipt of METI Minister's Award at the Fiscal 2016 National Commendation for Invention for discovery of diabetes treatment agent canagliflozin (Canaglu)

November  ▶ Establishment of MT Pharma (Thailand), a pharmaceutical sales company, in Thailand

2017

February  ▶ Receipt of Okochi Memorial Technology Prize at the 63rd Okochi Prize awards for fingolimod hydrochloride, a treatment agent for MS

April  ▶ Establishment of Tanabe Palm Service, which will be certified as a special subsidiary

August  ▶ Launch of Radicava, an ALS treatment agent, in the U.S.

September  ▶ Start of operations of BIKEN Co., a vaccine production joint venture
           ▶ Launch of Canalia (Tenelia-Canaglu combination drug), a treatment agent for type 2 diabetes mellitus

October  ▶ Transfer of generic drugs business to Nipro
           ▶ NeuroDerm, of Israel, a pharmaceutical development company, became a consolidated subsidiary

November  ▶ Launch of Rupafin, a treatment agent for allergic disorders

2018

February  ▶ Stelic Institute & Co., a pharmaceutical development company, became a consolidated subsidiary

April  ▶ Establishment of Mitsubishi Tanabe Pharma Canada, a pharmaceutical sales company, in Canada

May  ▶ Diabetes treatment agent Canagliflozin, which has a revolutionary treatment concept, won the Technology Award Grand Prize from the Japan Chemical Industry Association (JCIA)